Brief: Simcere Pharmaceutical Posts H1 Revenue Of RMB 3,585 Million
21/08/2025 14:30
Aug 21 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: H1 REVENUE RMB 3,585 MILLION H1 NET INCOME RMB 604 MILLION H1 BASIC EPS RMB 0.25 Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660